Veterinary Autogenous Vaccines for Poultry in Europe-Many Ways to Crack an Egg.

In the past decade, European animal farming has increasingly used autogenous vaccines for the prevention of nonnotifiable diseases. In Europe, these vaccines are exclusively inactivated bacterial and viral vaccines, with a set of specific regulations that differentiate them from conventional vaccines. The highest number of applications most likely occurs in poultry, as these animal species are farmed in the highest numbers compared with other types of food-producing animals. In 2019, autogenous vaccines came within the scope of harmonized European regulation for the first time, although many important aspects are still missing and need to be further developed. Consequently, several important legal provisions remain in national legislations and can vary tremendously between different member states of the European Union. The inclusion of autogenous vaccines in the management of certain diseases of poultry is justified by the nonavailability of licensed vaccines and the evolution and diversity of antigens in the field that are not covered by licensed vaccines. In addition, these vaccines aid in reducing the use of antibiotics. The methods for isolating and typing pathogenic isolates to obtain relevant antigens are pathogen specific and require a careful approach based on clinical evidence. Manufacturing processes are optimized according to regulatory standards, and they represent the most critical factor influencing the quality of autogenous vaccines and their placement on the market. This review presents the important requirements for manufacturing autogenous vaccines for poultry in addition to the relevant regulatory considerations. The results from a survey of several European Union member states regarding specific provisions within their national legislations are also presented.

Vacunas veterinarias autógenas para la avicultura en Europa: "Varias formas de romper un huevo". En la última década, la ganadería europea ha utilizado cada vez más vacunas autógenas para la prevención de enfermedades no declarables. En Europa, estas vacunas son exclusivamente vacunas inactivadas bacterianas y virales, con un conjunto de regulaciones específicas que las diferencian de las vacunas convencionales. El mayor número de aplicaciones probablemente se produce en la avicultura, ya que estas especies animales se crían en mayor número en comparación con otros tipos de animales productores de alimentos. En el año 2019, las vacunas autógenas entraron por primera vez en el ámbito de aplicación de una regulación europea armonizada, aunque todavía faltan muchos aspectos importantes y es necesario desarrollarlos más. En consecuencia, varias disposiciones legales importantes permanecen en las legislaciones nacionales y pueden variar enormemente entre los diferentes estados miembros de la Unión Europea. La inclusión de vacunas autógenas en el manejo de determinadas enfermedades avícolas se justifica por la falta de disponibilidad de vacunas autorizadas y la evolución y diversidad de antígenos en el campo que no están cubiertos por vacunas con licencia. Además, estas vacunas ayudan a reducir el uso de antibióticos. Los métodos para aislar y tipificar aislados patógenos para obtener antígenos relevantes son específicos de cada patógeno y requieren un enfoque cuidadoso basado en evidencia clínica. Los procesos de fabricación se optimizan de acuerdo con las normas reglamentarias y representan el factor más crítico que influye en la calidad de las vacunas autógenas y su comercialización. Esta revisión presenta los requisitos importantes para la fabricación de vacunas autógenas en la avicultura, además de las consideraciones regulatorias relevantes. También se presentan los resultados de una encuesta realizada en varios estados miembros de la Unión Europea sobre disposiciones específicas dentro de sus legislaciones nacionales.

Deletion of accessory genes 3a, 3b, 5a or 5b from avian coronavirus infectious bronchitis virus induces an attenuated phenotype both in vitro and in vivo.

Avian coronavirus infectious bronchitis virus (IBV) infects domestic fowl, resulting in respiratory disease and causing serious losses in unprotected birds. Its control is mainly achieved by using live attenuated vaccines. Here we explored the possibilities for rationally attenuating IBV to improve our knowledge regarding the function of IBV accessory proteins and for the development of next-generation vaccines with the recently established reverse genetic system for IBV H52 based on targeted RNA recombination and selection of recombinant viruses in embryonated eggs. To this aim, we selectively removed accessory genes 3a, 3b, 5a and 5b individually, and rescued the resulting recombinant (r) rIBV-Δ3a, rIBV-Δ3b, rIBV-Δ5a and rIBV-Δ5b. In vitro inoculation of chicken embryo kidney cells with recombinant and wild-type viruses demonstrated that the accessory protein 5b is involved in the delayed activation of the interferon response of the host after IBV infection. Embryo mortality after the inoculation of 8-day-old embryonated chicken eggs with recombinant and wild-type viruses showed that rIBV-Δ3b, rIBV-Δ5a and rIBV-Δ5b had an attenuated phenotype in ovo, with reduced titres at 6 h p.i. and 12 h p.i. for all viruses, while growing to the same titre as wild-type rIBV at 48 h p.i. When administered to 1-day-old chickens, rIBV-Δ3a, rIBV-Δ3b, rIBV-Δ5a and rIBV-Δ5b showed reduced ciliostasis in comparison to the wild-type viruses. In conclusion, individual deletion of accessory genes in IBV H52 resulted in mutant viruses with an attenuated phenotype.

Recombinant live attenuated avian coronavirus vaccines with deletions in the accessory genes 3ab and/or 5ab protect against infectious bronchitis in chickens.

Avian coronavirus infectious bronchitis virus (IBV) is a respiratory pathogen of chickens, causing severe economic losses in poultry industry worldwide. Live attenuated viruses are widely used in both the broiler and layer industry because of their efficacy and ability to be mass applied. Recently, we established a novel reverse genetics system based on targeted RNA recombination to manipulate the genome of IBV strain H52. Here we explore the possibilities to attenuate IBV in a rational way in order to generate safe and effective vaccines against virulent IBV (van Beurden et al., 2017). To this end, we deleted the nonessential group-specific accessory genes 3 and/or 5 in the IBV genome by targeted RNA recombination and selected the recombinant viruses in embryonated eggs. The resulting recombinant (r) rIBV-Δ3ab, rIBV-Δ5ab, and rIBV-Δ3ab5ab could be rescued and grew to the same virus titer as recombinant and wild type IBV strain H52. Thus, genes 3ab and 5ab are not essential for replication in ovo. When administered to one-day-old chickens, rIBV-Δ3ab, rIBV-Δ5ab, and rIBV-Δ3ab5ab showed reduced ciliostasis as compared to rIBV H52 and wild type H52, indicating that the accessory genes contribute to the pathogenicity of IBV. After homologous challenge with the virulent IBV strain M41, all vaccinated chickens were protected against disease based on reduced loss of ciliary movement in the trachea compared to the non-vaccinated but challenged controls. Taken together, deletion of accessory genes 3ab and/or 5ab in IBV resulted in mutant viruses with an attenuated phenotype and the ability to induce protection in chickens. Hence, targeted RNA recombination based on virulent IBV provides opportunities for the development of a next generation of rationally designed live attenuated IBV vaccines.

A reverse genetics system for avian coronavirus infectious bronchitis virus based on targeted RNA recombination.

BACKGROUND: Avian coronavirus infectious bronchitis virus (IBV) is a respiratory pathogen of chickens that causes severe economic losses in the poultry industry worldwide. Major advances in the study of the molecular biology of IBV have resulted from the development of reverse genetics systems for the highly attenuated, cell culture-adapted, IBV strain Beaudette. However, most IBV strains, amongst them virulent field isolates, can only be propagated in embryonated chicken eggs, and not in continuous cell lines. METHODS: We established a reverse genetics system for the IBV strain H52, based on targeted RNA recombination in a two-step process. First, a genomic and a chimeric synthetic, modified IBV RNA were co-transfected into non-susceptible cells to generate a recombinant chimeric murinized (m) IBV intermediate (mIBV). Herein, the genomic part coding for the spike glycoprotein ectodomain was replaced by that of the coronavirus mouse hepatitis virus (MHV), allowing for the selection and propagation of recombinant mIBV in murine cells. In the second step, mIBV was used as the recipient. To this end a recombination with synthetic RNA comprising the 3'-end of the IBV genome was performed by introducing the complete IBV spike gene, allowing for the rescue and selection of candidate recombinants in embryonated chicken eggs. RESULTS: Targeted RNA recombination allowed for the modification of the 3'-end of the IBV genome, encoding all structural and accessory genes. A wild-type recombinant IBV was constructed, containing several synonymous marker mutations. The in ovo growth kinetics and in vivo characteristics of the recombinant virus were similar to those of the parental IBV strain H52. CONCLUSIONS: Targeted RNA recombination allows for the generation of recombinant IBV strains that are not able to infect and propagate in continuous cell lines. The ability to introduce specific mutations holds promise for the development of rationally designed live-attenuated IBV vaccines and for studies into the biology of IBV in general.

A combinational approach of multilocus sequence typing and other molecular typing methods in unravelling the epidemiology of Erysipelothrix rhusiopathiae strains from poultry and mammals.

Erysipelothrix rhusiopathiae infections re-emerged as a matter of great concern particularly in the poultry industry. In contrast to porcine isolates, molecular epidemiological traits of avian E. rhusiopathiae isolates are less well known. Thus, we aimed to (i) develop a multilocus sequence typing (MLST) scheme for E. rhusiopathiae, (ii) study the congruence of strain grouping based on pulsed-field gel electrophoresis (PFGE) and MLST, (iii) determine the diversity of the dominant immunogenic protein SpaA, and (iv) examine the distribution of genes putatively linked with virulence among field isolates from poultry (120), swine (24) and other hosts (21), including humans (3). Using seven housekeeping genes for MLST analysis we determined 72 sequence types (STs) among 165 isolates. This indicated an overall high diversity, though 34.5% of all isolates belonged to a single predominant ST-complex, STC9, which grouped strains from birds and mammals, including humans, together. PFGE revealed 58 different clusters and congruence with the sequence-based MLST-method was not common. Based on polymorphisms in the N-terminal hyper-variable region of SpaA the isolates were classified into five groups, which followed the phylogenetic background of the strains. More than 90% of the isolates harboured all 16 putative virulence genes tested and only intI, encoding an internalin-like protein, showed infrequent distribution. MLST data determined E. rhusiopathiae as weakly clonal species with limited host specificity. A common evolutionary origin of isolates as well as shared SpaA variants and virulence genotypes obtained from avian and mammalian hosts indicates common reservoirs, pathogenic pathways and immunogenic properties of the pathogen.

Malignant lymphoma of T-cell origin in a Humboldt penguin (Spheniscus humboldti) and a pink-backed pelican (Pelecanus rufescens).

Multicentric T-cell lymphomas were diagnosed in two birds from separate zoological collections: one in a 27-year-old female Humboldt penguin (Spheniscus humboldti) and the second in an adult pink-backed pelican (Pelecanus rufescens). The main clinical sign in the penguin was dysphagia caused by lymphoma formation in the esophagus. Besides the esophageal lymphoma, neoplastic lymphoid cells were observed in the adrenal glands, liver, kidneys, lung, proventriculus, and gizzard. The pelican was found dead without a clinical history. Neoplastic lymphoid cells were observed in the kidneys, liver, pancreas, spleen, ventriculus, and small intestine. Neoplastic cells of the penguin as well as of the pelican were immunoreactive to CD3 antigen, suggesting the lymphomas were of T-cell origin. In both cases, test results were negative for Marek's disease virus, avian leukosis virus, and reticuloendotheliosis virus. In the pelican, a skin melanoma was diagnosed on the left throat pouch in addition to the multicentric T-cell lymphoma.

[Mycoplasma synoviae-associated egg-pole shell defects in laying hens]. / Mycoplasma synoviae-assoziierte Eischalenpoldefekte bei Legehennen.

Hens laying eggs with egg-pole shell defects (EPS) were examined in a clinical prospective study. 86 hens with EPS and 72 hens without EPS from three flocks were selected for this study. It could be proven serologically that hens with EPS had significant (p < 0.05) higher titers against Mycoplasma (M.) synoviae then hens without EPS. PCR tested cloacal swabs for M. synoviae were more frequently positive from hens with EPS (87%; n=72) then from hens without EPS (18%; n=13). Furthermore, M. synoviae could be cultivated from the oviduct of five hens with EPS. Additionally, M. synoviae-DNA was detectable in the albumen of nearly all eggs with EPS (n=48; 98%), contrary to the eggs without EPS (n=11; 26%). Ultrastructural investigation revealed that eggs with EPS showed considerable differences of the egg shell structure as well as the cross section dimension according to eggs without EPS. Due to the significantly more frequent detection of M. synoviae-DNA from the cloaca of chickens with EPS, is an involvement of M. synoviae in laying of EPS in the surveyed herds likely. Further infection experiments with the isolated M. synoviae were not perfomed, therefore about the causal pathogenic role of M. synoviae in the development of eggs with EPS in the surveyed herds can only be speculated.

Acute paretic syndrome in juvenile White Leghorn chickens resembles late stages of acute inflammatory demyelinating polyneuropathies in humans.

BACKGROUND: Sudden limb paresis is a common problem in White Leghorn flocks, affecting about 1% of the chicken population before achievement of sexual maturity. Previously, a similar clinical syndrome has been reported as being caused by inflammatory demyelination of peripheral nerve fibres. Here, we investigated in detail the immunopathology of this paretic syndrome and its possible resemblance to human neuropathies. METHODS: Neurologically affected chickens and control animals from one single flock underwent clinical and neuropathological examination. Peripheral nervous system (PNS) alterations were characterised using standard morphological techniques, including nerve fibre teasing and transmission electron microscopy. Infiltrating cells were phenotyped immunohistologically and quantified by flow cytometry. The cytokine expression pattern was assessed by quantitative real-time PCR (qRT-PCR). These investigations were accomplished by MHC genotyping and a PCR screen for Marek's disease virus (MDV). RESULTS: Spontaneous paresis of White Leghorns is caused by cell-mediated, inflammatory demyelination affecting multiple cranial and spinal nerves and nerve roots with a proximodistal tapering. Clinical manifestation coincides with the employment of humoral immune mechanisms, enrolling plasma cell recruitment, deposition of myelin-bound IgG and antibody-dependent macrophageal myelin-stripping. Disease development was significantly linked to a 539 bp microsatellite in MHC locus LEI0258. An aetiological role for MDV was excluded. CONCLUSIONS: The paretic phase of avian inflammatory demyelinating polyradiculoneuritis immunobiologically resembles the late-acute disease stages of human acute inflammatory demyelinating polyneuropathy, and is characterised by a Th1-to-Th2 shift.